- Home
- CHRS
as 06-13-2025 4:00pm EST
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 112.5M | IPO Year: | 2014 |
| Target Price: | $4.68 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $2.43 | Next Earning Date: | 08-07-2025 |
| Revenue: | $272,251,000 | Revenue Growth: | 19.87% |
| Revenue Growth (this year): | -80.98% | Revenue Growth (next year): | 132.69% |
Stock Insider Trading Activity of Coherus BioSciences Inc. (CHRS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wahlstrom Mats | CHRS | Director | May 23 '25 | Sell | $0.74 | 99,988 | $73,881.13 | 0 |
Latest Coherus BioSciences Inc. News
CHRS Breaking Stock News: Dive into CHRS Ticker-Specific Updates for Smart Investing
Insider Monkey
8 days ago
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
GlobeNewswire
16 days ago
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
GlobeNewswire
19 days ago
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
Simply Wall St.
a month ago
Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations
Thomson Reuters StreetEvents
a month ago
Q1 2025 Coherus BioSciences Inc Earnings Call
GuruFocus.com
a month ago
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ...
Zacks
a month ago
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Associated Press Finance
a month ago
Coherus BioSciences: Q1 Earnings Snapshot
Compare CHRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CHRS Coherus BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.